March 7th 2024
Patients with phlebotomy-dependent polycythemia vera, a type of myeloproliferative neoplasm, treated with rusfertide experienced greater responses compared with those treated with placebo.
FDA Approval Sought for Pacritinib to Treat Myelofibrosis With Severe Thrombocytopenia
October 14th 2020A rolling submission of a new drug application (NDA) for the JAK2/FLT3 inhibitor pacritinib has been initiated for patients with myelofibrosis and severe thrombocytopenia defined as platelet counts of less than 50,000 μL.